Market Overview

J&J's Janssen-Cilag's ZYTIGA Receives Positive EU Recommendation

Share:
Related JNJ
Benzinga's M&A Chatter for Tuesday, August 25, 2015
Fast Money Traders Give Their Opinion On What To Buy In This Sell-Off
Ride The Market With Johnson & Johnson (Seeking Alpha)

J&J's (NYSE: JNJ) Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA® (abiraterone acetate) for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.1 If endorsed by the European Commission, the recommendation would expand the indication for ZYTIGA®, which is currently approved for use in combination with prednisone/prednisolone to treat men with mCRPC whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Posted-In: News FDA

 

Related Articles (JNJ)

View Comments and Join the Discussion!

Get Benzinga's Newsletters